A retrospective clinical study on the combination of traditional Chinese and Western medicine in the treatment of limited-disease small cell lung cancer
Not Applicable
Completed
- Conditions
- Small-cell Lung Cancer
- Registration Number
- ITMCTR2200005625
- Lead Sponsor
- Guang'anmen Hospital, China Academy of Chinese Medicine Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
(1) The age ranges from 18 to 75 years.
(2) Patients with localized SCLC with clear pathological diagnosis, following NCCN clinical guidelines, and receiving standardized treatment such as chest radiotherapy, chemotherapy, or prophylactic brain irradiation.
(3) Survival time > 3 months.
(4) The integrated Chinese and Western medicine treatment group received TCM treatment =6 months.
Exclusion Criteria
(1) complicated with serious diseases of heart, liver, kidney and hematopoietic system.
(2) other types of primary malignancy.
(3) pregnant women, mental patients and patients suffering from other malignant tumors.
(4) Patients who have participated in clinical trials of new drugs.
(5) Absence of basic information.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-Free Survival;
- Secondary Outcome Measures
Name Time Method overall survival;